<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Molecular Pathology</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC59975E-26E8-4A62-ABD8-A570DC6ABF06"><gtr:id>FC59975E-26E8-4A62-ABD8-A570DC6ABF06</gtr:id><gtr:name>Keele University</gtr:name><gtr:address><gtr:line1>Keele</gtr:line1><gtr:line4>Newcastle</gtr:line4><gtr:line5>Staffordshire</gtr:line5><gtr:postCode>ST5 5BG</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/84CBC165-4691-450F-9345-6C226573026C"><gtr:id>84CBC165-4691-450F-9345-6C226573026C</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Webb</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/441128F3-D178-4FBD-BC48-FA7C9D99DA22"><gtr:id>441128F3-D178-4FBD-BC48-FA7C9D99DA22</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Swerdlow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8C3C602-541B-498F-9F55-2F76387FE34E"><gtr:id>B8C3C602-541B-498F-9F55-2F76387FE34E</gtr:id><gtr:firstName>Amanda</gtr:firstName><gtr:surname>Swain</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E78313EF-B2FD-4FE8-987E-F0E13BA6CB24"><gtr:id>E78313EF-B2FD-4FE8-987E-F0E13BA6CB24</gtr:id><gtr:firstName>Colin Stephen</gtr:firstName><gtr:surname>Cooper</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7910ADC1-0186-440A-B7DF-E8F1807432B9"><gtr:id>7910ADC1-0186-440A-B7DF-E8F1807432B9</gtr:id><gtr:firstName>David Paul</gtr:firstName><gtr:surname>Dearnaley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C5EA052E-91B5-4408-ACD8-63E2FBE255D4"><gtr:id>C5EA052E-91B5-4408-ACD8-63E2FBE255D4</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Workman</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/942D2AA5-E744-4398-84D8-E1B53CDCDD55"><gtr:id>942D2AA5-E744-4398-84D8-E1B53CDCDD55</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Parker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1D20065C-DD9B-4CA9-8597-56BB5EE78FE0"><gtr:id>1D20065C-DD9B-4CA9-8597-56BB5EE78FE0</gtr:id><gtr:firstName>Johann</gtr:firstName><gtr:otherNames>Sebastian</gtr:otherNames><gtr:surname>de Bono</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/120D7D32-14D9-453D-BFB0-464837DE2C49"><gtr:id>120D7D32-14D9-453D-BFB0-464837DE2C49</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Stratton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9F5349A0-9D89-4C54-8661-566ED92B81A4"><gtr:id>9F5349A0-9D89-4C54-8661-566ED92B81A4</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:surname>Shipley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/37BAE3A9-6E75-41F4-B7B7-2FDEA0329E42"><gtr:id>37BAE3A9-6E75-41F4-B7B7-2FDEA0329E42</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Wooster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6503D588-752A-4655-95D3-DB8E0EDB1C09"><gtr:id>6503D588-752A-4655-95D3-DB8E0EDB1C09</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Foster</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FC1E9EAB-9C28-45F5-B748-5215470A9333"><gtr:id>FC1E9EAB-9C28-45F5-B748-5215470A9333</gtr:id><gtr:firstName>R</gtr:firstName><gtr:surname>Eeles</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501019"><gtr:id>23E61516-FF33-450F-B9A8-8DAA17EA0AD8</gtr:id><gtr:title>Proposal for the renewal of funds for the NCRI s South of England Prostate Cancer Collaborative</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501019</gtr:grantReference><gtr:abstractText>See Section 9 of the report</gtr:abstractText><gtr:technicalSummary>Our Prostate Cancer Collaborative (PCC) is dedicated to key areas of translational research that will continue, over the next 5 years, to impact on prostate cancer patients lives. Namely the PCC aims: to develop improved markers for the clinical management of prostate cancer; to develop better strategies for managing patients will localised disease; to develop better drugs and treating patients with hormone refractory prostate cancer; and to improve our understanding of the genetics and aetiology of prostate cancer. We believe that in the long term the strategy outlined in these proposals will allow the development of several areas of research where the PCC will be internationally competitive and in some cases occupy unique niches. By the end of the second 5 year NCRI award we expect to maintain our strong portfolios in Cancer Genetics and Radiotherapy but additionally have fully developed programmes in Molecular Pathology (clinical marker identification), Developmental Biology and Drug Development linked to Phase I/II clinical trials. We believe that by this time will also have several internationally unique programmes including (i) Active Surveillance Trials linked both to clinical marker studies and to tertiary chemoprevention trials, (ii) marker studies linked to large epidemiological studies (EPIC-PROSTATE), and (iii) marker analyses linked to the Translatlantic Prostate Association (TAPA) study. Several of these initiatives (eg Active Surveillance , Genetics, Radiotherapy, Drug Development) are anticipated to have significant impacts on the management of prostate cancer patients both nationally and internationally.</gtr:technicalSummary><gtr:fund><gtr:end>2009-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1941049</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Molecular genetic analysis of prostate cancer</gtr:description><gtr:id>2B5A5AA7-839F-4087-8B31-DAD7AAB850A7</gtr:id><gtr:impact>Publication in Section 2. Search 'Neal' .</gtr:impact><gtr:outcomeId>E2CB642BC02-1</gtr:outcomeId><gtr:partnerContribution>Collaboration on several key projects aimed at understanding the genetics and natural history of prostate cancer</gtr:partnerContribution><gtr:piContribution>Collaboration on expression profiling of human prostate, cancer, biomarker discovery and genetic analysis of prostate cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Keele University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Life Sciences</gtr:department><gtr:description>Apoptosis in prostate cancer</gtr:description><gtr:id>86B42B70-6537-4722-A696-07A906E08E6E</gtr:id><gtr:impact>PMID: 19023142</gtr:impact><gtr:outcomeId>37A9FBD4508-2</gtr:outcomeId><gtr:partnerContribution>We have colaborated in investigating the role of apoptosis control in prostate cancer development.For a small investment in infrastructure we hav ereorientated the interests of this group towards prostate cancer</gtr:partnerContribution><gtr:piContribution>Provision of infrastructure to work on prostate cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Keele University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Apoptosis in prostate cancer</gtr:description><gtr:id>CDA421C2-C4DB-49E2-9F0C-79DF20A3AB95</gtr:id><gtr:impact>PMID: 19023142</gtr:impact><gtr:outcomeId>37A9FBD4508-1</gtr:outcomeId><gtr:partnerContribution>We have colaborated in investigating the role of apoptosis control in prostate cancer development.For a small investment in infrastructure we hav ereorientated the interests of this group towards prostate cancer</gtr:partnerContribution><gtr:piContribution>Provision of infrastructure to work on prostate cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Pathology of prostate cancer</gtr:description><gtr:id>17DEF635-5C1B-4541-AA64-B6B21489A916</gtr:id><gtr:impact>Publication in section 2 (search Foster CS)</gtr:impact><gtr:outcomeId>5D894BBECEB-1</gtr:outcomeId><gtr:partnerContribution>this group has provided pathology that has underpinned prostate cancer biomarker discovery</gtr:partnerContribution><gtr:piContribution>Collaboration on biomarker discovery</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cancer Epidemiology Unit</gtr:department><gtr:description>Aetiology of prostate cancer</gtr:description><gtr:id>E575C6BD-F4CA-43F3-82A3-C47B353EAD4D</gtr:id><gtr:impact>Publications listed in section 2 (search Key T author)</gtr:impact><gtr:outcomeId>4B8B6BF3D25-1</gtr:outcomeId><gtr:partnerContribution>Collection of samples from the EPIC study</gtr:partnerContribution><gtr:piContribution>This work has formed part of the NCRI prostate cancer collaborative</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public Lectures</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>87558C1A-6256-4D44-AF9C-A0844E0C159B</gtr:id><gtr:impact>Member of the Collaborative have given many public lectured. For example Paul Workman has given CRUK lectures including 'Drugging the Cancer Genome: Design of personalised cancer medicines' specifically highlighting drugs relevant to prostate cancer including PI3K and HSP90. His work has been highlighted as Editors choice in Drug Discovery Today (http://newsletter.drugdiscoverytoday.com/generated/default/f14/theview.htm)

Education of the public and health professionals</gtr:impact><gtr:outcomeId>431B94DD028</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://newsletter.drugdiscoverytoday.com/generated/default/f14/theview.htm</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Running national prostate charity</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>1EE07D47-2EAA-450C-847E-B66718D2AB26</gtr:id><gtr:impact>Professor Cooper was involved in setting up a national prostate cancer charity called 'everyman' aimed at raising awareness of issue relating to prostate cancer

National awareness of under funding of prostate cancer research. Awareness of symptoms.</gtr:impact><gtr:outcomeId>35490787672</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Membership of patient groups</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>A9B3EC7A-7277-4FC6-9D4A-C30B673A1C97</gtr:id><gtr:impact>Dr Parker is medical advisor to PCaSO Prostate Cancer Network, and has close links to the Prostate Cancer Support Federation, speaking at their launch meeting in 2007 and at 'The Great PSA debate' they hosted in 2009. has been a member of the Prostate Cancer Charter for Action Steering Group (2002-2005), and the Prostate Cancer Charity Research Strategy Review Committee. Recruitment to the Active Surveillance study has been facilitated by liaison with the Prostate Cancer Charity, the Prostate Cancer Support Organisation (PCaSO), and the PSA Prostate Cancer Support Association. Prof Dearnaley was an advisor to Prostate Cancer Research UK's &amp;quot;Ignorance isn't Bliss&amp;quot; Campaign. Prof Cooper and Prof Foster are on the scientific advisory boards of Tenovus and The Prostate Cancer Charity.

Education of prostate cancer patinets. Assisting in changing public policy.</gtr:impact><gtr:outcomeId>229A7306175</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Freemasons' Grand Charity Career Award (10 years)</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>The Freemasons' Grand Charity</gtr:fundingOrg><gtr:id>88538A45-543F-4EBF-8A20-0A5FF4E54A44</gtr:id><gtr:outcomeId>DD4FBDFCDA20</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>288000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NCRI Infrastructure renewal</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>National Cancer Research Institute (NCRI)</gtr:fundingOrg><gtr:id>3B94E9FF-DB00-464E-928D-1B19EE4BAFB8</gtr:id><gtr:outcomeId>jhyxG4muxHH0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Competitive Reserch Applications</gtr:description><gtr:end>2011-08-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>9CDD9A4C-01B5-41CB-8821-A9024298AFEC</gtr:id><gtr:outcomeId>B3EA68332B60</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>380000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK funding (The NCRI Prostate Cancer Collaborative 'Prostate Cancer Map Project')</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>87D5FD2C-2AE2-4426-9CE0-CE4A2AB7DE8F</gtr:id><gtr:outcomeId>CFAEBD358940</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Competitive Research Application</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Prostate Cancer UK</gtr:fundingOrg><gtr:id>E88946E9-2E3F-4AE4-91ED-564B383DA58C</gtr:id><gtr:outcomeId>NRRRgeMrF1a0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Changing UK Clinical Practice</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8FE9F048-ED54-4931-8F80-AD09228FB4AF</gtr:id><gtr:impact>Prof Dearnaley contributed to the COIN/Royal College of Radiologists' guidelines on Radiotherapy for Prostate Cancer, the COIN/BAUS guidelines for prostate cancer as well as the NICE Improving Outcomes in Urological Cancer Manual and was CI on the Phase 3 RCT's which established dose escalated conformal radiotherapy as the national standard of care in NICE Guidance. He has led the clinical contribution to NICE's consideration of IMRT. Prof Foster is a member of the NHS Prostate Cancer Scientific Advisory Committee and Chairman of the Consensus Report on the Prostate Biopsy for the N.H.S. Cancer Screening Committee (2003). Dr Parker was a member of the NICE Prostate Cancer Guideline Development Group, and the ESMO Prostate Cancer Guideline Group. The NICE guideline for the first time included Active Surveillance as a standard option for patients with early localised prostate cancer.</gtr:impact><gtr:outcomeId>2F44FCB761B</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A. Patients represented on Tissue Microarrays (n=1817) 1. In-house Tissue Microarray from Prostatectomy and TURP specimens (n=260) Contacts: Professor Colin Cooper, Dr Rosalind Eeles 2. Danish TMA. Samples from prostatectomy patients (n=218) Contacts: Dr Michael Borre, Dr Chris Parker 3. TransAtlantic Prostate Group (TAPG). Samples from TURP specimens (n=700) Contacts: Professor Jack Cuzick, Professor Colin Cooper 4. The Viking TMA. Samples from TURPS (n=199) Contacts: Dr Michael Borre, Dr Chris Parker 5. Biopsy TMAs from Active Surveillance Patients (n=200) Contact: Dr Chris Parker 6. Biopsy TMAs MRC RT01 from Radiotherapy Trial Patients (n=200) Contact: Dr Chris Parker Future biopsy TMA construction The ongoing construction of TMAs is an essential activity that underpins our NCRI PCC Biomarker Programme (Section 4.2.2). We are continuing to construct biopsy TMAs from patients entered the Active Surveillance and MRC RT01 Radiotherapy Trials; and we hope to double the markers of patients represented in the biopsyTMAs to 400 in each case. The TAPG TMA is to be extended to a further 700 prostate cancers. We will also construct biopsy TMAs from additional trials such as the RADICALS trials and the MRC PR07 Radiotherapy Trial and from biopsies collected through links to the EPIC study and Professor Tim Key. As a joint initiative with NCRI ProMPT Collaboration we will assist in the production of biopsy TMAs for the ProtecT trial. B. Collection of Fresh Frozen Prostatectomy slices (n=330) We have developed a new method for collecting frozen prostate slices.1 Nearly 200 slices have now been collected. A similar system has also been adopted by the ProMPT PCC and Professor Neal has now collected 150 slices. Future Collection of Frozen Slices We are collecting frozen flices now at a rate of 100-150 per year. This is an essential activity that underpins the NCRI Prostate Cancer Map Project (Section 4.2.3). C. Samples from Castration Resistant Disease 1. Frozen samples from castration resistant prostate cancer. 130 samples from 52 patients; include a mixture of samples from various organs, prostate, lymph nodes, liver, intra-abdominal soft tissue mets, and bone mets. 2. Formalin fixed samples from castration resistant prostate cancer. Samples from 8 patients: samples from prostates and various other sites. 3. Prostate cancer patients treated each year in Phase I/II clinical trials with new drugs. 100-200 per year. D. Patient bloods and Tissue blocks from prostate cancer family studies and young men with prostate cancer Dr Rosalind Eeles has collected and used 1854 bloods from individuals with a family history of prostate cancer or from men diagnosed with prostate cancer at &amp;lt;60 years of age in Genome Wide Association Studies.2 These were compared to a similar number of controls from the ProtecT study in a collaboration between the two PCCs. Around 1000 blocks of formalin fixed cancer tissue have also been collected from these patient groups. The collection of additional specimens continues. 1) men with family prostate cancer: bloods from approx 100 men per year 2) men diagnosed with prostate cancer at &amp;lt;60 years of age: bloods from approx 500 men per year. E. Systematically collected blood specimens Currently 3000 cases have been entered into this collection of clinical dataset for all cases are available in the Bob Champion clinical database.</gtr:description><gtr:id>A203099C-FD53-4115-82BB-1C46CBC6D805</gtr:id><gtr:impact>These materials and linked database have been used by over 20 research groups nationally and internationally.</gtr:impact><gtr:outcomeId>84DB7702719</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Prostate cancer clinical samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>39239EBD-4F36-4A7A-BC7D-BD896BE4A3DE</gtr:id><gtr:title>The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aebddcb3a950a46dafb6e76a71689277"><gtr:id>aebddcb3a950a46dafb6e76a71689277</gtr:id><gtr:otherNames>Whitaker HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>44C18BF074F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4AB2940-3A27-44B0-8D05-D5F153BB5787</gtr:id><gtr:title>Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44222c78ec454beafd9c72ad49d6c46e"><gtr:id>44222c78ec454beafd9c72ad49d6c46e</gtr:id><gtr:otherNames>Chan F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>2215C0B5C49</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DF4A831-9AA0-42DB-BEDF-74F491A5FB3F</gtr:id><gtr:title>A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>C61FE297B37</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF12E3D7-0AB3-406F-9818-A2174979B18D</gtr:id><gtr:title>CYP17 inhibition as a hormonal strategy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb6185d79137a579b502858f48f0b280"><gtr:id>fb6185d79137a579b502858f48f0b280</gtr:id><gtr:otherNames>Reid AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1743-4270</gtr:issn><gtr:outcomeId>8F04E81FA8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6838A446-A5AD-4C62-855D-8CFE13A59C1A</gtr:id><gtr:title>Ribosomal protein l19 is a prognostic marker for human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d96b73aadcfe493258b0bd922ccfcb7"><gtr:id>2d96b73aadcfe493258b0bd922ccfcb7</gtr:id><gtr:otherNames>Bee A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>6AA2C0951F8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18C8C392-2AA5-4D66-AEC4-F2905D1D6ADF</gtr:id><gtr:title>HDAC inhibitors and cardiac safety.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12b39e9a2a764dd6d123137af82cbef4"><gtr:id>12b39e9a2a764dd6d123137af82cbef4</gtr:id><gtr:otherNames>Molife R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>D9C18014731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D45EDA2-42A0-4855-B2B2-E01D7C746884</gtr:id><gtr:title>A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>343D7D615EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6F1AAA-69C1-4F87-9ACD-3D8A46CD9034</gtr:id><gtr:title>Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2d29e1a83bf5535e630740c0c77efbd"><gtr:id>d2d29e1a83bf5535e630740c0c77efbd</gtr:id><gtr:otherNames>Auvinen A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>3EC972CFAE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>281617B2-4BB3-49C3-B5FE-5AE50E542F5C</gtr:id><gtr:title>Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/594845e96170f39f94390e7891030f08"><gtr:id>594845e96170f39f94390e7891030f08</gtr:id><gtr:otherNames>Murthy V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>B13753D780A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EDBFC9E-90E2-4E6C-899C-F2C499522DCB</gtr:id><gtr:title>Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa925f4297f1eb3ccbf37a295ec2f752"><gtr:id>fa925f4297f1eb3ccbf37a295ec2f752</gtr:id><gtr:otherNames>Allen NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>1759AF973EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>179028CB-09FF-426E-A4EA-79F5CCFEDF2A</gtr:id><gtr:title>Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population.</gtr:title><gtr:parentPublicationTitle>The International journal of biological markers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0393-6155</gtr:issn><gtr:outcomeId>293082E7C6C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4B59B0D-EF78-41BA-B20A-266F4A043659</gtr:id><gtr:title>Assessing correlations between the spatial distribution of the dose to the rectal wall and late rectal toxicity after prostate radiotherapy: an analysis of data from the MRC RT01 trial (ISRCTN 47772397).</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68d0b20cc7b4a60cc062341333892bd7"><gtr:id>68d0b20cc7b4a60cc062341333892bd7</gtr:id><gtr:otherNames>Buettner F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>D9749FC6679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73FC654B-82AA-4F52-A826-96B51534F0F6</gtr:id><gtr:title>Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5107fd3e9a9c9395e302e24321a54841"><gtr:id>5107fd3e9a9c9395e302e24321a54841</gtr:id><gtr:otherNames>Henderson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>2F4FEABCD9A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>12129CF9-EBE4-4FEA-A034-5CA85175BBE3</gtr:id><gtr:title>Prognostic significance of osteopontin expression in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc2d8d91bf879d884ccff7f7d338a070"><gtr:id>dc2d8d91bf879d884ccff7f7d338a070</gtr:id><gtr:otherNames>Forootan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>3A18C96F54D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAFE644F-5890-45B4-A727-3F8506073D09</gtr:id><gtr:title>Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/97a217dfcdb081d545cb2c5774c88d4b"><gtr:id>97a217dfcdb081d545cb2c5774c88d4b</gtr:id><gtr:otherNames>Morgan SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>AE6C5A434FA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A11AE8A-5184-4E87-B5A9-A224B73F294B</gtr:id><gtr:title>Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f39ae2276b369e770fa032951358aa7f"><gtr:id>f39ae2276b369e770fa032951358aa7f</gtr:id><gtr:otherNames>Mitra A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>830AAE7FC60</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44616FE2-8245-4028-8BD3-4A70D31B4588</gtr:id><gtr:title>How not to detect prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b8c0f9f2a167a9c3c7bdc612ef4685c"><gtr:id>1b8c0f9f2a167a9c3c7bdc612ef4685c</gtr:id><gtr:otherNames>Parker CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>E2F1BAD2092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EC45EF6-B455-4577-B4E5-EDB494C405C4</gtr:id><gtr:title>Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>7FBCB872F48</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D7E6E22-ADE5-42F3-9B12-89E2497E0F3E</gtr:id><gtr:title>Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays.</gtr:title><gtr:parentPublicationTitle>The Journal of molecular diagnostics : JMD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e46ef7cf2b1a9aa57b3d01ad597fc6f"><gtr:id>8e46ef7cf2b1a9aa57b3d01ad597fc6f</gtr:id><gtr:otherNames>Jhavar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1525-1578</gtr:issn><gtr:outcomeId>852C1972FE0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335213FC-3A39-4057-9A44-C3AF558C9C4C</gtr:id><gtr:title>CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49be2b5e2213be95387c40511c7eb168"><gtr:id>49be2b5e2213be95387c40511c7eb168</gtr:id><gtr:otherNames>Ang JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>A39F5F6A128</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A808747C-F48F-43F6-BD06-DC12B7FDCF45</gtr:id><gtr:title>Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>A1D8605772D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7290EE81-2F7C-4842-9524-02779AFC635D</gtr:id><gtr:title>Keynote comment: Chemoprevention of cancer--time to catch up with the cardiologists.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>02AF555683A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EC167A1-D226-4783-B176-B40A5B32F29F</gtr:id><gtr:title>Jack Cuzick: working to improve cancer prevention and detection.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3ec0a83af6bbd03b3b2f496ca58e4a0"><gtr:id>e3ec0a83af6bbd03b3b2f496ca58e4a0</gtr:id><gtr:otherNames>Pincock S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>736A63BCCCD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E603033-FC77-40E2-BE33-77803BF6CFD3</gtr:id><gtr:title>DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39a2ae33a6dd8ba7d14b57dfcb09b45b"><gtr:id>39a2ae33a6dd8ba7d14b57dfcb09b45b</gtr:id><gtr:otherNames>Low L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>A1D4406A9FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF0D6349-202E-4085-947F-BB23AEA4C166</gtr:id><gtr:title>Prostate cancer: neither vitamin E nor selenium prevents prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa925f4297f1eb3ccbf37a295ec2f752"><gtr:id>fa925f4297f1eb3ccbf37a295ec2f752</gtr:id><gtr:otherNames>Allen NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>6A0FD36D41D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6699765-FDB2-43EC-8310-A9D69F291DCE</gtr:id><gtr:title>Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8236ec1f49e52ca4589e5f476c47982b"><gtr:id>8236ec1f49e52ca4589e5f476c47982b</gtr:id><gtr:otherNames>Kattan MW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>63EDB3A36D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3269B3A1-D535-4B96-BFB7-21EF6513B98D</gtr:id><gtr:title>Bayesian belief network for the Gleason patterns in prostatic adenocarcinoma: development of a diagnostic decision support system for educational purposes.</gtr:title><gtr:parentPublicationTitle>Analytical and quantitative cytology and histology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91782a165e260ba6042ea6ac78708828"><gtr:id>91782a165e260ba6042ea6ac78708828</gtr:id><gtr:otherNames>Montironi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0884-6812</gtr:issn><gtr:outcomeId>E7A1D916AE5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94C32048-4F38-4A0A-8E2B-8E9CCB16B72C</gtr:id><gtr:title>Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>99BC416B03F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9D1DA5E-E8B7-4076-9746-73165C24375E</gtr:id><gtr:title>Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/177ff490b37490fa8cad6a5e646938b8"><gtr:id>177ff490b37490fa8cad6a5e646938b8</gtr:id><gtr:otherNames>Pischon T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>03A8E679E35</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B93A87DE-64F7-479F-B181-7AC6B9A13B8B</gtr:id><gtr:title>Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41bf1a45a9842156c5330cadbd2eeb56"><gtr:id>41bf1a45a9842156c5330cadbd2eeb56</gtr:id><gtr:otherNames>Stanley S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>DBD716A9BCA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5C58E48-8E22-4068-BAB9-1923314A6C41</gtr:id><gtr:title>A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d06044b5b980691bde9945b100e3f6d"><gtr:id>4d06044b5b980691bde9945b100e3f6d</gtr:id><gtr:otherNames>South CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>7C4ABD41847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AE9A3F3-0E04-45F5-9513-275632ECDD51</gtr:id><gtr:title>Diagnostic radiation procedures and risk of prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b9077f5dd8402aa1a115f8b9a5b11a3"><gtr:id>1b9077f5dd8402aa1a115f8b9a5b11a3</gtr:id><gtr:otherNames>Myles P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>227600DCF8B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4BFB93E-5899-4E5C-B814-CB90C3C1A47E</gtr:id><gtr:title>Multiple loci with different cancer specificities within the 8q24 gene desert.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71e2ebd1f2b2b3fb1e5851e7c43fcdba"><gtr:id>71e2ebd1f2b2b3fb1e5851e7c43fcdba</gtr:id><gtr:otherNames>Ghoussaini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>2F27CD698C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40C88236-2052-4F9B-AEB1-002FCA02F314</gtr:id><gtr:title>Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a73d99ef8c5d89c7efa34880edfd5b6d"><gtr:id>a73d99ef8c5d89c7efa34880edfd5b6d</gtr:id><gtr:otherNames>Nilsson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>F313DFBCF4D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2703AC26-C2C6-4D34-94C3-2C00043B87CF</gtr:id><gtr:title>Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>DDCFF974A19</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE658030-4E02-4A1C-B648-6396B26AA816</gtr:id><gtr:title>Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies.</gtr:title><gtr:parentPublicationTitle>Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f39abb4910084c154cf0b3e3ded784b7"><gtr:id>f39abb4910084c154cf0b3e3ded784b7</gtr:id><gtr:otherNames>Oliver T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0080-0015</gtr:issn><gtr:outcomeId>A8AC61060BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>622460CE-7B0B-446B-856C-76ABEFC7E2F5</gtr:id><gtr:title>Efficacy of low-dose dexamethasone in castration-refractory prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>676E6E69C09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DBCD8BD-F493-4280-B461-38B4230F424A</gtr:id><gtr:title>Comparative studies of intracellular Ca2+ in strongly and weakly metastatic rat prostate cancer cell lines.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1307c1bd9200c4cb415555ce015701b"><gtr:id>e1307c1bd9200c4cb415555ce015701b</gtr:id><gtr:otherNames>Ding Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>22130299503</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C08887D-A463-4605-B0C2-EABCAE9B430B</gtr:id><gtr:title>Feasibility of familial PSA screening: psychosocial issues and screening adherence.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80ed2e73366b0ebf2e7e4112489d8881"><gtr:id>80ed2e73366b0ebf2e7e4112489d8881</gtr:id><gtr:otherNames>Sweetman J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>7EEA828B61F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4251E40-55F9-46DE-BA9A-99683623A32A</gtr:id><gtr:title>Clinical implications of introducing a new PSA assay.</gtr:title><gtr:parentPublicationTitle>International urology and nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-1623</gtr:issn><gtr:outcomeId>D5570033811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>582C4F91-56D2-48B3-A91A-1D30545D7C69</gtr:id><gtr:title>Variability of bladder filling in patients receiving radical radiotherapy to the prostate.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc844308f060e720b2a9736e9ce49bc8"><gtr:id>cc844308f060e720b2a9736e9ce49bc8</gtr:id><gtr:otherNames>O'Doherty UM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>4A960CD3F71</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A3146EF-834B-4AFC-9FC8-6A7CA88A5383</gtr:id><gtr:title>A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>39AEDAF8812</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4FCE73E0-6DEB-49F9-BC1D-317F3A3505DC</gtr:id><gtr:title>Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a987d8fe811f020393f6d2a0d8ee023"><gtr:id>5a987d8fe811f020393f6d2a0d8ee023</gtr:id><gtr:otherNames>Crowe FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>FBC0EB040A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39177259-9BB9-41D8-B6F4-70C3CB270995</gtr:id><gtr:title>The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/675570658e2e1d0dbdcfb855b2d08e81"><gtr:id>675570658e2e1d0dbdcfb855b2d08e81</gtr:id><gtr:otherNames>Stephens RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>CB4FA2B5003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F023644-4207-4845-BB42-A799CCE6F792</gtr:id><gtr:title>Epidermal growth factor potentiates in vitro metastatic behaviour of human prostate cancer PC-3M cells: involvement of voltage-gated sodium channel.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff3ceae1207120ce0c68b52e6514ae37"><gtr:id>ff3ceae1207120ce0c68b52e6514ae37</gtr:id><gtr:otherNames>Uysal-Onganer P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>E27B588E297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3C4F04F-5EE6-460F-B5EB-77453A31E02E</gtr:id><gtr:title>Detection of occult spinal cord compression with magnetic resonance imaging of the spine.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>6BCFFAC311D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2EDA0696-4A33-4515-AA92-43157214D452</gtr:id><gtr:title>A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41b9e3d2abbbbe905442165f8f2fc1a6"><gtr:id>41b9e3d2abbbbe905442165f8f2fc1a6</gtr:id><gtr:otherNames>Rowinsky EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>B3D7D08497B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C49AF220-CE96-4B46-977C-07AB0727647D</gtr:id><gtr:title>The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>15486147BA5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2655B4C4-2B3B-4F57-8B10-A1B3553384AD</gtr:id><gtr:title>Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4da106ff90ea5e7644df5f6705e72dd7"><gtr:id>4da106ff90ea5e7644df5f6705e72dd7</gtr:id><gtr:otherNames>Youles M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>08A147C8E27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCC837E5-BCCD-47D7-9F29-26A2C5F9D04F</gtr:id><gtr:title>A role for notch signaling in stromal survival and differentiation during prostate development.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9d15ca0513265914ded31d1942d6a2b"><gtr:id>a9d15ca0513265914ded31d1942d6a2b</gtr:id><gtr:otherNames>Orr B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>E58B50B739A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3172B649-A40E-49F4-8866-F795D2B55756</gtr:id><gtr:title>Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf164b6b41a48ba54462bb6ac62004dc"><gtr:id>bf164b6b41a48ba54462bb6ac62004dc</gtr:id><gtr:otherNames>de Bono JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>FC52F344DC9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39AB6BB4-2213-4806-8119-5BF3AAB2E947</gtr:id><gtr:title>Notch signalling and voltage-gated Na+ channel activity in human prostate cancer cells: independent modulation of in vitro motility.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccdd6422c9fce110ae3ea4f809bcfb87"><gtr:id>ccdd6422c9fce110ae3ea4f809bcfb87</gtr:id><gtr:otherNames>Scorey N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>2B514FB5DCC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A51D7B97-BCC4-463C-B2F9-30D9ECEB52BC</gtr:id><gtr:title>Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7de56984409165cceda55c03b8e4e7e9"><gtr:id>7de56984409165cceda55c03b8e4e7e9</gtr:id><gtr:otherNames>Takimoto CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>F44DF70A786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D7EA71D-8600-4CB1-8800-ADF1D9117CF9</gtr:id><gtr:title>Targeting CYP17: established and novel approaches in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a47a480c4dfc6358b9a2a6fcc3232896"><gtr:id>a47a480c4dfc6358b9a2a6fcc3232896</gtr:id><gtr:otherNames>Yap TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1471-4892</gtr:issn><gtr:outcomeId>04E87E3D490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>561B7B3A-1202-4238-8106-F005EFE77862</gtr:id><gtr:title>A versatile phantom for quality assurance in the UK Medical Research Council (MRC) RT01 trial (ISRCTN47772397) in conformal radiotherapy for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb6d90dffd1678735234573f7e504db5"><gtr:id>fb6d90dffd1678735234573f7e504db5</gtr:id><gtr:otherNames>Moore AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>1DA6525F71F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>640C687A-20E1-4014-9B49-A16977387CD8</gtr:id><gtr:title>Direct-aperture optimization applied to selection of beam orientations in intensity-modulated radiation therapy.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d36ae1577604c2737a0693980c23e034"><gtr:id>d36ae1577604c2737a0693980c23e034</gtr:id><gtr:otherNames>Bedford JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>5C958F17834</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68D4AC2F-98D4-4565-8846-D2E76555C0B0</gtr:id><gtr:title>NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33bc6e001ed42152a5afd2aefb93c68a"><gtr:id>33bc6e001ed42152a5afd2aefb93c68a</gtr:id><gtr:otherNames>Eccles SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>2A104A15E02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>689C6A18-CC80-47D0-8D9B-60188F4DB749</gtr:id><gtr:title>Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d48520cd614288173d025e920ecbae17"><gtr:id>d48520cd614288173d025e920ecbae17</gtr:id><gtr:otherNames>Wilke DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>99F0EF09866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>315CAD94-AEDE-4442-84E3-5404A8968BA4</gtr:id><gtr:title>Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf164b6b41a48ba54462bb6ac62004dc"><gtr:id>bf164b6b41a48ba54462bb6ac62004dc</gtr:id><gtr:otherNames>de Bono JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>DE592ACEB0A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>952BAB31-5C16-447B-AEBE-620ADBA4EEB3</gtr:id><gtr:title>Preparation and characterization of prostate cell lines for functional cloning studies to identify regulators of apoptosis.</gtr:title><gtr:parentPublicationTitle>Journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59460f82b4f3c554f1f2872bf40d05e5"><gtr:id>59460f82b4f3c554f1f2872bf40d05e5</gtr:id><gtr:otherNames>Pickard MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0196-3635</gtr:issn><gtr:outcomeId>5ADFF433615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>580838F8-1262-41E1-A2D3-93D94C60D306</gtr:id><gtr:title>A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb3a4c4aac6c39218e08d4481cd8d8dc"><gtr:id>bb3a4c4aac6c39218e08d4481cd8d8dc</gtr:id><gtr:otherNames>Tolbert WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>786AA2D2BF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34B8C0EB-4D32-468F-824F-CBF7D9BE2D6F</gtr:id><gtr:title>RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery).</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>8BC0AE4AB09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F07ED2C-7675-4C3B-8AAD-5A9D6CB7C82A</gtr:id><gtr:title>Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d7a96f83d49892ff93edb8db1ac087"><gtr:id>45d7a96f83d49892ff93edb8db1ac087</gtr:id><gtr:otherNames>Berney DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>3F19242876A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D12072C5-6D5A-464D-9B6B-2B8434F01AD3</gtr:id><gtr:title>New prostate cancer drug: Prostate cancer's day in the sun.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>700C3495B4E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>792A7687-EFAE-408D-A17F-A9320AE07D12</gtr:id><gtr:title>Long-term outcome among men with conservatively treated localised prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>90CADD06F4D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB765E0F-24B0-46FB-AD87-F380C4E295EC</gtr:id><gtr:title>Sexual activity and prostate cancer risk in men diagnosed at a younger age.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ad757638bf6e6a427110748ca55cff7"><gtr:id>6ad757638bf6e6a427110748ca55cff7</gtr:id><gtr:otherNames>Dimitropoulou P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>A328D845577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AF83507-86EB-433B-AF9A-6CC91EAE80C5</gtr:id><gtr:title>Outcome of early detection and radiotherapy for occult spinal cord compression.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>266590D5CE7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F0C61EF-E7AD-4C1B-B65C-F5E4D79A1884</gtr:id><gtr:title>Activity-dependent regulation of voltage-gated Na+ channel expression in Mat-LyLu rat prostate cancer cell line.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491a4a051028639fe5a363c4f1372e9a"><gtr:id>491a4a051028639fe5a363c4f1372e9a</gtr:id><gtr:otherNames>Brackenbury WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>7ACC10615A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B3385F3-412D-46BB-A0CB-AA26D070FADA</gtr:id><gtr:title>Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature clinical practice. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee4d7988610ad4501cf4d5fd67f385f"><gtr:id>9ee4d7988610ad4501cf4d5fd67f385f</gtr:id><gtr:otherNames>Cooper CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1743-4270</gtr:issn><gtr:outcomeId>61B1D5A4513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01FA6F13-0569-4FEE-B30B-00AAB77108E5</gtr:id><gtr:title>TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4e9cc0c2e19b7ff2acbdc17c7857da1"><gtr:id>a4e9cc0c2e19b7ff2acbdc17c7857da1</gtr:id><gtr:otherNames>Knight JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>28114159A5C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8388C52-4B27-41E3-9339-ADEFBE0E2F46</gtr:id><gtr:title>Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bb05bf8cd8392c69268e36ce470dec9"><gtr:id>6bb05bf8cd8392c69268e36ce470dec9</gtr:id><gtr:otherNames>van der Kwast TH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>2166A88E343</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4BECC04-3BB3-4887-B6A5-915436683BEA</gtr:id><gtr:title>Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of medical imaging and radiation oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1754-9477</gtr:issn><gtr:outcomeId>17C16B6AE1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DACCE1CF-2FA3-45CC-86B9-C8B45AE19A70</gtr:id><gtr:title>Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e871e82bbdf1eacaf51aebe347d3cdeb"><gtr:id>e871e82bbdf1eacaf51aebe347d3cdeb</gtr:id><gtr:otherNames>Chi KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>8340FE881B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B9AF5C1-EC66-4F5E-AED3-868C07061725</gtr:id><gtr:title>Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>0C5BC5C6A96</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5B4FB28-37D7-405E-81C2-8B85E023E0F6</gtr:id><gtr:title>Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC).</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1513b0c6d9acc01d11fa40a454fa02"><gtr:id>cf1513b0c6d9acc01d11fa40a454fa02</gtr:id><gtr:otherNames>Travis RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn><gtr:outcomeId>AC13A80A715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>064BF252-9BF5-4DEC-9B56-F6D816248C4A</gtr:id><gtr:title>Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a71af17ab23169ccaa01135ba3297c2"><gtr:id>2a71af17ab23169ccaa01135ba3297c2</gtr:id><gtr:otherNames>Langley RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>54485950842</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E911C6B7-3A3F-4106-AC5E-9E06A14E5365</gtr:id><gtr:title>Concepts of epigenetics in prostate cancer development.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee4d7988610ad4501cf4d5fd67f385f"><gtr:id>9ee4d7988610ad4501cf4d5fd67f385f</gtr:id><gtr:otherNames>Cooper CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>E9990FBC85C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB3C994D-5BB8-4DF2-A2E6-8A17A18F606C</gtr:id><gtr:title>Complex patterns of ETS gene alteration arise during cancer development in the human prostate.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edc5f7c0e58dfe61e7f81d9f8d2b7544"><gtr:id>edc5f7c0e58dfe61e7f81d9f8d2b7544</gtr:id><gtr:otherNames>Clark J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>0B54D212F93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F96677B-F627-4A4D-A708-A028D25FD18C</gtr:id><gtr:title>Synthesis and use of isotope-labelled substrates for a mechanistic study on human alpha-methylacyl-CoA racemase 1A (AMACR; P504S).</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18c9cfcc831944f21a4c1b6caed306f6"><gtr:id>18c9cfcc831944f21a4c1b6caed306f6</gtr:id><gtr:otherNames>Darley DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>8457DF7F5AD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BD0E609-5E99-4DAD-A81C-0951FC9C7373</gtr:id><gtr:title>Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: clinical potential of neonatal Nav1.5 in breast cancer.</gtr:title><gtr:parentPublicationTitle>European journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/903ae193b0d243269141c03dc3352fac"><gtr:id>903ae193b0d243269141c03dc3352fac</gtr:id><gtr:otherNames>Onkal R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0014-2999</gtr:issn><gtr:outcomeId>B162626D3B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20F05268-B78B-46B5-8163-1ABD8D9FAB45</gtr:id><gtr:title>Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90fb521fb4609dc795b90be3158eb5e1"><gtr:id>90fb521fb4609dc795b90be3158eb5e1</gtr:id><gtr:otherNames>Song H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>C235D158616</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3F3C95F-493C-44CF-AF37-5A17AD749F6E</gtr:id><gtr:title>Radiotherapy in locally advanced prostate cancer.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e27cd06336d1272223579a135a640bd"><gtr:id>5e27cd06336d1272223579a135a640bd</gtr:id><gtr:otherNames>Tan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>9BC9E8CADE8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>125B2326-8E96-4C20-BC3A-4B505C3FE13D</gtr:id><gtr:title>Increased expression of Id family proteins in small cell lung cancer and its prognostic significance.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/060ff5887c8f518c90aea1e8d2d518b1"><gtr:id>060ff5887c8f518c90aea1e8d2d518b1</gtr:id><gtr:otherNames>Kamalian L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>6DA32A5F707</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F453D262-E2CD-4FC5-8058-16B865F584EA</gtr:id><gtr:title>Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b668591801917e7cdc9c1c9229a35d04"><gtr:id>b668591801917e7cdc9c1c9229a35d04</gtr:id><gtr:otherNames>Mita AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>AC797C54987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2668029-B34C-4A91-93A7-731B2757E4BF</gtr:id><gtr:title>Prostate cancer: PSA as an intermediate end point in clinical trials.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>EE4E558F506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F110E222-A7AB-401C-94FA-6F55DE4C386A</gtr:id><gtr:title>p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/111a8e6406270f6279743c3f40da2fdd"><gtr:id>111a8e6406270f6279743c3f40da2fdd</gtr:id><gtr:otherNames>Kudahetti S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>D32FB613F94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F96EB442-BF1D-4E1A-8394-E70EFEE60C86</gtr:id><gtr:title>Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford).</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d0dd9e08c2c8452860a4d7254570e76"><gtr:id>3d0dd9e08c2c8452860a4d7254570e76</gtr:id><gtr:otherNames>Key TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>C06E98DD6A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>471DB985-0731-4493-A80A-782F330A7D58</gtr:id><gtr:title>A comparison of the use of bony anatomy and internal markers for offline verification and an evaluation of the potential benefit of online and offline verification protocols for prostate radiotherapy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5efc8b71f5001a4f8cc08071ef89d6"><gtr:id>bf5efc8b71f5001a4f8cc08071ef89d6</gtr:id><gtr:otherNames>McNair HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>CD952D85DBC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8150D0E7-1055-40D4-A111-62C9F3E993C0</gtr:id><gtr:title>Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4e687e7e62db23388559e46d798d39c"><gtr:id>f4e687e7e62db23388559e46d798d39c</gtr:id><gtr:otherNames>Eeles RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>4751DA01F09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4157B9C-110A-4ABA-9DCA-323A927ABCF2</gtr:id><gtr:title>A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>CA2FEBCEB94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>830A17BA-A8A5-4C4C-B462-3841738385E4</gtr:id><gtr:title>Late gastrointestinal toxicity after dose-escalated conformal radiotherapy for early prostate cancer: results from the UK Medical Research Council RT01 trial (ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a28fc121b1e2b4b05013e918f994750d"><gtr:id>a28fc121b1e2b4b05013e918f994750d</gtr:id><gtr:otherNames>Syndikus I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>06F45DE9169</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3CE6C00-8075-41D0-891B-131B21A1B943</gtr:id><gtr:title>Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4584d57f16d6e14b88fcb8e9d4d5626c"><gtr:id>4584d57f16d6e14b88fcb8e9d4d5626c</gtr:id><gtr:otherNames>Foster CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>8CF1A5818C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EA38F64-7CF7-4450-8FC7-31D0995072D9</gtr:id><gtr:title>Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdec94f393eaf497c630ae3f65a48507"><gtr:id>cdec94f393eaf497c630ae3f65a48507</gtr:id><gtr:otherNames>Khoo VS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>D120FD2B3EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1802E4F5-8169-48B2-9730-86A8E3FBD1DE</gtr:id><gtr:title>Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e46ef7cf2b1a9aa57b3d01ad597fc6f"><gtr:id>8e46ef7cf2b1a9aa57b3d01ad597fc6f</gtr:id><gtr:otherNames>Jhavar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>1EED69F21B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CB1454F-8AA7-4E6B-8446-31558DC18593</gtr:id><gtr:title>Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a32b45b31a2cdf6d894c4ab0b50a52fd"><gtr:id>a32b45b31a2cdf6d894c4ab0b50a52fd</gtr:id><gtr:otherNames>Kote-Jarai Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>42F844074FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C1DA3D6-C53C-407F-A353-C048DD026233</gtr:id><gtr:title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>D09F6625B5E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B9E375C-3979-4CDB-A427-643161355893</gtr:id><gtr:title>Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases with clinical outcome.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d7a96f83d49892ff93edb8db1ac087"><gtr:id>45d7a96f83d49892ff93edb8db1ac087</gtr:id><gtr:otherNames>Berney DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>DADC71F938F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF30598-2A08-4CB9-986D-EE877A2588E7</gtr:id><gtr:title>Words of wisdom. Re: needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>C438355DB84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>656CE1B4-B44C-4A24-A896-FA229ED37DC7</gtr:id><gtr:title>An improved method for constructing tissue microarrays from prostate needle biopsy specimens.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a02af01542b73e653694fb5eb667eb6"><gtr:id>1a02af01542b73e653694fb5eb667eb6</gtr:id><gtr:otherNames>McCarthy F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>0F65A5CC5C1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4370015A-D228-4328-95C8-AE364BB6F08A</gtr:id><gtr:title>Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd45906bf540f35a3ca2ee233c637e6"><gtr:id>2fd45906bf540f35a3ca2ee233c637e6</gtr:id><gtr:otherNames>Jackson AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>4B920B70003</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD2A39FF-489C-4C58-B803-8245B62A9482</gtr:id><gtr:title>Germ-line mutations in mismatch repair genes associated with prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ebdef0231b3b333dca4bd2f5a87771d"><gtr:id>7ebdef0231b3b333dca4bd2f5a87771d</gtr:id><gtr:otherNames>Grindedal EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>5BA55A14240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98662F97-5056-4FF4-824E-9971022A1251</gtr:id><gtr:title>International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58bfd71fbbd42020ba6ceca87a1fcda7"><gtr:id>58bfd71fbbd42020ba6ceca87a1fcda7</gtr:id><gtr:otherNames>Shaw GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>3A933D36572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>651BE717-A0B6-4BF6-8614-16B1DCE51B79</gtr:id><gtr:title>One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b9cb7909f356f80391a6a69c4962c0"><gtr:id>a4b9cb7909f356f80391a6a69c4962c0</gtr:id><gtr:otherNames>Johansson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>82C2BA4BDE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>124E1C24-39D1-4F30-AF7B-AFFC31FA3B57</gtr:id><gtr:title>A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/116576ae71b70349068564a6f9700df5"><gtr:id>116576ae71b70349068564a6f9700df5</gtr:id><gtr:otherNames>Melia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>DF72F15BA00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72FE555B-EEDE-4354-8F41-BFF88A03B5ED</gtr:id><gtr:title>Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: status of endogenous citrate and dependence on aconitase and fatty acid synthase.</gtr:title><gtr:parentPublicationTitle>The international journal of biochemistry &amp; cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e06488f928c16acba186c511dcd19"><gtr:id>ab2e06488f928c16acba186c511dcd19</gtr:id><gtr:otherNames>Mycielska ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1357-2725</gtr:issn><gtr:outcomeId>6927C4373D0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1947B08-16E3-466D-B2E2-3183D388F61C</gtr:id><gtr:title>Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58d5f9d487d1e3e8e1eddf3ebc47094b"><gtr:id>58d5f9d487d1e3e8e1eddf3ebc47094b</gtr:id><gtr:otherNames>van As NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>AD801E451BB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BDEE039-8338-4EB1-B6FB-D599F9EF40F5</gtr:id><gtr:title>A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe453426d3dcebe714f7a8f82373574"><gtr:id>cbe453426d3dcebe714f7a8f82373574</gtr:id><gtr:otherNames>Sarker D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>54F512C3FE4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE38BC0F-54D9-48F6-9715-3411FA04CE38</gtr:id><gtr:title>Synthetic approaches to peptides containing the L-Gln-L-Val-D(S)-Dmt motif.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a0a2351993dbff6935d5032b5136d51"><gtr:id>2a0a2351993dbff6935d5032b5136d51</gtr:id><gtr:otherNames>Suaifan GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>E4923A7B9B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A68510D-372A-4BE2-93C7-232020589C88</gtr:id><gtr:title>Dynamic contrast-enhanced MRI for prostate cancer localization.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd45906bf540f35a3ca2ee233c637e6"><gtr:id>2fd45906bf540f35a3ca2ee233c637e6</gtr:id><gtr:otherNames>Jackson AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>BA7261C4CC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73264BE4-CC6B-4C23-BA21-79BDA598CC99</gtr:id><gtr:title>Physical activity and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/12d32f5772c5c036af67ea4d8bd4d720"><gtr:id>12d32f5772c5c036af67ea4d8bd4d720</gtr:id><gtr:otherNames>Johnsen NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>679F1C99035</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1167E62A-B7B6-4913-BC8D-AD9B520984FA</gtr:id><gtr:title>Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/594845e96170f39f94390e7891030f08"><gtr:id>594845e96170f39f94390e7891030f08</gtr:id><gtr:otherNames>Murthy V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>7461206098B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>305A38C4-61DA-44ED-B2E5-C88AB70F1181</gtr:id><gtr:title>A study of Gleason score interpretation in different groups of UK pathologists; techniques for improving reproducibility.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88e64a33627a4a494807223e00e4b78a"><gtr:id>88e64a33627a4a494807223e00e4b78a</gtr:id><gtr:otherNames>Griffiths DF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>62D83651CBF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B2DF67CE-1BCC-4E98-80A8-38DF59CD888E</gtr:id><gtr:title>A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc4295554e46bd9d2b5c0085c76c00c2"><gtr:id>dc4295554e46bd9d2b5c0085c76c00c2</gtr:id><gtr:otherNames>Carducci MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-543X</gtr:issn><gtr:outcomeId>A61FBC72960</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4508AD8C-FF3A-4928-9397-230265F9F0B5</gtr:id><gtr:title>Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05f18341caf580a208e3260fe7ae54ad"><gtr:id>05f18341caf580a208e3260fe7ae54ad</gtr:id><gtr:otherNames>Plummer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>876A2D179EF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5B5ED53-9987-4043-9040-8B3F53DAAAF3</gtr:id><gtr:title>The relevance of a hypoxic tumour microenvironment in prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c37f799329bbe36bda8a1ed60d551c"><gtr:id>72c37f799329bbe36bda8a1ed60d551c</gtr:id><gtr:otherNames>Stewart GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>18A3779939D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD0B608-24E4-41F3-8F1B-148FAE135EAE</gtr:id><gtr:title>Brn-3a neuronal transcription factor functional expression in human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2e774f43f615ca5c00453f6129505d"><gtr:id>6d2e774f43f615ca5c00453f6129505d</gtr:id><gtr:otherNames>Diss JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>85F51471D76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAEBC039-7766-4A13-A565-CFD4306E9198</gtr:id><gtr:title>Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A).</gtr:title><gtr:parentPublicationTitle>Molecular and cellular neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2e774f43f615ca5c00453f6129505d"><gtr:id>6d2e774f43f615ca5c00453f6129505d</gtr:id><gtr:otherNames>Diss JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1044-7431</gtr:issn><gtr:outcomeId>48C06CB64CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CC8A597-3EC7-4AA7-9801-07F29866F7D1</gtr:id><gtr:title>Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0393f08ffaf5b0eb75ef8685b0e29198"><gtr:id>0393f08ffaf5b0eb75ef8685b0e29198</gtr:id><gtr:otherNames>Maloney A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>EFD932BBD1E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7167F9BA-0666-4A85-BFC3-35C13F92A8B1</gtr:id><gtr:title>The antiapoptotic RBM5/LUCA-15/H37 gene and its role in apoptosis and human cancer: research update.</gtr:title><gtr:parentPublicationTitle>TheScientificWorldJournal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3a4cd63f939f88d34eefdb80628c287"><gtr:id>e3a4cd63f939f88d34eefdb80628c287</gtr:id><gtr:otherNames>Maarabouni MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1537-744X</gtr:issn><gtr:outcomeId>7157125A054</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18FF81E6-5BE9-426F-932F-418F50317D7C</gtr:id><gtr:title>Putting the heat on cancer.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acfc3fc3032aa1ca2c1d9e812cb8be4c"><gtr:id>acfc3fc3032aa1ca2c1d9e812cb8be4c</gtr:id><gtr:otherNames>Workman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>7F1DB92B0BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77C47FA9-7F04-4112-B8CE-EF33974F1023</gtr:id><gtr:title>Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/465500d95966eaf15b951db1d4e0ba72"><gtr:id>465500d95966eaf15b951db1d4e0ba72</gtr:id><gtr:otherNames>Scher HI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>04F78B3F720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F86D8A5-40A8-4993-BB7E-94375DE05749</gtr:id><gtr:title>Prostatic pathology reporting in the UK: development of a national external quality assurance scheme.</gtr:title><gtr:parentPublicationTitle>Histopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f9530d792f4f14adc7eb562a2d7c0702"><gtr:id>f9530d792f4f14adc7eb562a2d7c0702</gtr:id><gtr:otherNames>Harnden P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0309-0167</gtr:issn><gtr:outcomeId>3C3FB0881FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA4673EE-6350-42A3-BED6-4D35273F7C35</gtr:id><gtr:title>Predictors of histological disease progression in untreated, localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6548b2f81f2116c6cf3a94a56ba8bccb"><gtr:id>6548b2f81f2116c6cf3a94a56ba8bccb</gtr:id><gtr:otherNames>Venkitaraman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>E43962B0CDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E87E3B9-7F6D-4E8E-A6A9-26374350F6EC</gtr:id><gtr:title>The role of Sox9 in prostate development.</gtr:title><gtr:parentPublicationTitle>Differentiation; research in biological diversity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce350f910b3fbceb089e8788fa4f4651"><gtr:id>ce350f910b3fbceb089e8788fa4f4651</gtr:id><gtr:otherNames>Thomsen MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-4681</gtr:issn><gtr:outcomeId>6079551A168</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>215CC7C9-23FE-4D93-A7F1-31DFCC9F8A71</gtr:id><gtr:title>Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92998bbc54836864480bfa0e73bb0649"><gtr:id>92998bbc54836864480bfa0e73bb0649</gtr:id><gtr:otherNames>Ng MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>F4EF42E4100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D77CB72E-DF89-4C78-AAD4-77BBBC2B1D1D</gtr:id><gtr:title>Identification of new genetic risk factors for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Asian journal of andrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e44cdeab746fb44de905c18382c13553"><gtr:id>e44cdeab746fb44de905c18382c13553</gtr:id><gtr:otherNames>Guy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1008-682X</gtr:issn><gtr:outcomeId>50BFDD58380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>647B18F1-55F5-48A3-9C1B-24216DEF2EB6</gtr:id><gtr:title>Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fd45906bf540f35a3ca2ee233c637e6"><gtr:id>2fd45906bf540f35a3ca2ee233c637e6</gtr:id><gtr:otherNames>Jackson AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>99F6FDB8346</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF6AE5FE-FCD8-4B3C-B7F1-9BB62366056A</gtr:id><gtr:title>Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be597218ce9e139e6afafc3614cbea31"><gtr:id>be597218ce9e139e6afafc3614cbea31</gtr:id><gtr:otherNames>Olmos D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>B522D528B90</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DC54262-9FB5-4A93-AE28-ED2B04058742</gtr:id><gtr:title>Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aca6db52c4cce4361d4e907eef1b981"><gtr:id>9aca6db52c4cce4361d4e907eef1b981</gtr:id><gtr:otherNames>Molife LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>09E01D18EC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82CC6123-B3F9-4609-8405-8062D03849C2</gtr:id><gtr:title>Multiple newly identified loci associated with prostate cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4e687e7e62db23388559e46d798d39c"><gtr:id>f4e687e7e62db23388559e46d798d39c</gtr:id><gtr:otherNames>Eeles RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>A5E7A4593B2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45721773-0DEE-4893-AF1D-69C4F25C08A7</gtr:id><gtr:title>Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7025793c71551379fdcd855374038f97"><gtr:id>7025793c71551379fdcd855374038f97</gtr:id><gtr:otherNames>Tolcher AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>DEA55401DD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4660BF4-8342-4029-9152-3688D65BA6F3</gtr:id><gtr:title>Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf164b6b41a48ba54462bb6ac62004dc"><gtr:id>bf164b6b41a48ba54462bb6ac62004dc</gtr:id><gtr:otherNames>de Bono JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>2E56F03EAD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A58EA27-6FB9-4F70-98B7-77ED9FCA046F</gtr:id><gtr:title>Screening for prostate cancer appears to work, but at what cost?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>CAEDCFCF06E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40D6BEA0-6933-4036-A95F-F06D464744C1</gtr:id><gtr:title>Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0bbce062611487939b1c1cfe787a8c8"><gtr:id>c0bbce062611487939b1c1cfe787a8c8</gtr:id><gtr:otherNames>Haluska P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>E8D223E1D87</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEE39A94-B220-4C3E-B9E4-169D6911F743</gtr:id><gtr:title>Diversity of TMPRSS2-ERG fusion transcripts in the human prostate.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edc5f7c0e58dfe61e7f81d9f8d2b7544"><gtr:id>edc5f7c0e58dfe61e7f81d9f8d2b7544</gtr:id><gtr:otherNames>Clark J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>7C559BC1069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66EC8998-878A-4931-9F3F-C157C4B077BF</gtr:id><gtr:title>Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/371098659e22cdd5302c9cd3d2532c2f"><gtr:id>371098659e22cdd5302c9cd3d2532c2f</gtr:id><gtr:otherNames>Chu QS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>BC17EACABE6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>850E218D-7705-41B9-B0CA-7121DDA7EC62</gtr:id><gtr:title>Epidermal growth factor upregulates motility of Mat-LyLu rat prostate cancer cells partially via voltage-gated Na+ channel activity.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1307c1bd9200c4cb415555ce015701b"><gtr:id>e1307c1bd9200c4cb415555ce015701b</gtr:id><gtr:otherNames>Ding Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>8FBDB2C2755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0411E0-3D25-4135-9132-884E2761B721</gtr:id><gtr:title>Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45d7a96f83d49892ff93edb8db1ac087"><gtr:id>45d7a96f83d49892ff93edb8db1ac087</gtr:id><gtr:otherNames>Berney DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>C0E15C030C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29B2AAC1-B7A9-4B64-A35A-0C67F261F3ED</gtr:id><gtr:title>Adjuvant radiotherapy after surgery for prostate cancer.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn><gtr:outcomeId>8A151397AA7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B22DEB3C-676C-4FD7-B32C-E5E05DF24F46</gtr:id><gtr:title>Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b82940093f846276a629cccde7cca8b9"><gtr:id>b82940093f846276a629cccde7cca8b9</gtr:id><gtr:otherNames>Olsson AY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>BF66C87658B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E7E72F2-17F3-4B6C-B08A-EFE666605729</gtr:id><gtr:title>The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95cbff3dcb07069b5196ff07035f2705"><gtr:id>95cbff3dcb07069b5196ff07035f2705</gtr:id><gtr:otherNames>Cuzick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>B10B0D98D63</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F4C8F63-C583-4650-8A4E-98EDCAC4A428</gtr:id><gtr:title>Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression.</gtr:title><gtr:parentPublicationTitle>International journal of oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b068700d2053d7b305c5a4fc87bbe38f"><gtr:id>b068700d2053d7b305c5a4fc87bbe38f</gtr:id><gtr:otherNames>Morgan EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1019-6439</gtr:issn><gtr:outcomeId>ADAFBE1853E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F9E0E7E-E95F-4A33-B36C-EBDD7618AF7D</gtr:id><gtr:title>Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bc86594b102aaa9a8a5b2a19fee8e4"><gtr:id>a3bc86594b102aaa9a8a5b2a19fee8e4</gtr:id><gtr:otherNames>Sydes MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>A60CADEB999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8649FACE-2BC3-437E-93E5-8C6D223BEDA3</gtr:id><gtr:title>Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4b9cb7909f356f80391a6a69c4962c0"><gtr:id>a4b9cb7909f356f80391a6a69c4962c0</gtr:id><gtr:otherNames>Johansson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>1E9DAE5BD34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26870D2F-06DA-4AD1-B3DB-06C88FC06C82</gtr:id><gtr:title>Targeting the PI3K/AKT pathway for the treatment of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe453426d3dcebe714f7a8f82373574"><gtr:id>cbe453426d3dcebe714f7a8f82373574</gtr:id><gtr:otherNames>Sarker D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>A59FFFAD2E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>092496D6-B379-4DB2-86AE-27E7F914A577</gtr:id><gtr:title>Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c70d8f63de3d1e0f6e91b30969ad3685"><gtr:id>c70d8f63de3d1e0f6e91b30969ad3685</gtr:id><gtr:otherNames>Endogenous Hormones and Prostate Cancer Collaborative Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>00BE9143571</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B349022-3784-4147-B004-7A07565D520D</gtr:id><gtr:title>Resolving the optimal timing of radiotherapy after radical prostatectomy: the need for further research.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>11D86C4668B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33BE1F68-7EEE-448F-B9A2-3E520415943F</gtr:id><gtr:title>Screening and prostate-cancer mortality in a randomized European study.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acd480942a7c078cf44c3187dcd3e92d"><gtr:id>acd480942a7c078cf44c3187dcd3e92d</gtr:id><gtr:otherNames>Schr?der FH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>A0BA2B23D61</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC99E88D-9536-4B8D-9FF9-332FE1FCAB2E</gtr:id><gtr:title>Expression profiling of CD133+ and CD133- epithelial cells from human prostate.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/093fc6d2660efa456f09e77f228a6612"><gtr:id>093fc6d2660efa456f09e77f228a6612</gtr:id><gtr:otherNames>Shepherd CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>789BB5FFF89</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92F66DF0-BAE3-40AF-A3D4-205DF0E1E5CF</gtr:id><gtr:title>Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa925f4297f1eb3ccbf37a295ec2f752"><gtr:id>fa925f4297f1eb3ccbf37a295ec2f752</gtr:id><gtr:otherNames>Allen NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>A3F8FE56C1C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7384720-39F6-43FB-BCD1-AD02152747B0</gtr:id><gtr:title>A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58d5f9d487d1e3e8e1eddf3ebc47094b"><gtr:id>58d5f9d487d1e3e8e1eddf3ebc47094b</gtr:id><gtr:otherNames>van As NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>0BFD18ACCD5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B37505D-41F7-4376-82CD-307348BB402C</gtr:id><gtr:title>Mesenchymal mechanisms in prostate organogenesis.</gtr:title><gtr:parentPublicationTitle>Differentiation; research in biological diversity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15ca68652030ac8a38ff4fd89585f7b5"><gtr:id>15ca68652030ac8a38ff4fd89585f7b5</gtr:id><gtr:otherNames>Thomson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-4681</gtr:issn><gtr:outcomeId>C95E59F893D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7918A199-AC0F-465A-AE74-20C2DE1BBB2D</gtr:id><gtr:title>Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies.</gtr:title><gtr:parentPublicationTitle>Genetic epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21c5ac3da15af6d05aab473b7e01c5fb"><gtr:id>21c5ac3da15af6d05aab473b7e01c5fb</gtr:id><gtr:otherNames>MacInnis RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0741-0395</gtr:issn><gtr:outcomeId>4A65631C8C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E93141E4-B465-42E5-B4B5-2F64C709009D</gtr:id><gtr:title>Evaluation of margining algorithms in commercial treatment planning systems.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/575e0a2595915220a4a67582c7d62d97"><gtr:id>575e0a2595915220a4a67582c7d62d97</gtr:id><gtr:otherNames>Pooler AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>C7DC50F0761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA05FCEB-50CE-456D-856D-F03A081FF2A3</gtr:id><gtr:title>Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.</gtr:title><gtr:parentPublicationTitle>Biochemical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4f5be68464293dc0cf7ac33307ad5d5"><gtr:id>c4f5be68464293dc0cf7ac33307ad5d5</gtr:id><gtr:otherNames>Knowles HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-2952</gtr:issn><gtr:outcomeId>D90428C2DCA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A152C397-F23B-46C0-8DBB-4D83777191CC</gtr:id><gtr:title>Constrained segment shapes in direct-aperture optimization for step-and-shoot IMRT.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d36ae1577604c2737a0693980c23e034"><gtr:id>d36ae1577604c2737a0693980c23e034</gtr:id><gtr:otherNames>Bedford JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>577D2409DF2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B703697B-1A7C-41A1-8C61-6BE4B309C01A</gtr:id><gtr:title>Tumor dosimetry on SPECT (186)Re-HEDP scans: variations in the results from the reconstruction methods used.</gtr:title><gtr:parentPublicationTitle>Cancer biotherapy &amp; radiopharmaceuticals</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad1d2197e0e91962e853f062fccf316d"><gtr:id>ad1d2197e0e91962e853f062fccf316d</gtr:id><gtr:otherNames>Divoli A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1084-9785</gtr:issn><gtr:outcomeId>8B90CF3F7CB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77CDB2A2-4A42-4F3A-9282-33746B05CD4B</gtr:id><gtr:title>Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>E35408C9BA4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C514BCE9-7688-4F4A-958D-9CE8E246FF9D</gtr:id><gtr:title>Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>9CC6592CF2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0229FA0A-5433-40FE-819E-9C60F450D947</gtr:id><gtr:title>Prostate development and pathogenesis.</gtr:title><gtr:parentPublicationTitle>Differentiation; research in biological diversity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15ca68652030ac8a38ff4fd89585f7b5"><gtr:id>15ca68652030ac8a38ff4fd89585f7b5</gtr:id><gtr:otherNames>Thomson AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0301-4681</gtr:issn><gtr:outcomeId>2914AF3B11D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>36F6D563-9D2B-4865-B78B-B3004861A1DF</gtr:id><gtr:title>Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63f1dd9fac024b84b36c7dcd9baf0863"><gtr:id>63f1dd9fac024b84b36c7dcd9baf0863</gtr:id><gtr:otherNames>Collin SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>5B5C431128A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABA2CEB0-8B1A-4330-A8CD-3B9C0B67E131</gtr:id><gtr:title>Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db5dd390fff4eb82dd140c867c64a164"><gtr:id>db5dd390fff4eb82dd140c867c64a164</gtr:id><gtr:otherNames>Gulliford SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>25B2734FCDE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E476540-1059-4919-9256-463D4D664920</gtr:id><gtr:title>Beta-subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro and in vivo analyses of mRNA expression.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d2e774f43f615ca5c00453f6129505d"><gtr:id>6d2e774f43f615ca5c00453f6129505d</gtr:id><gtr:otherNames>Diss JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>3ACD115C084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDF30D07-BFE8-4841-904C-058D67EE278B</gtr:id><gtr:title>A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4fd560c99e312494f45973c7f1901de1"><gtr:id>4fd560c99e312494f45973c7f1901de1</gtr:id><gtr:otherNames>Steele NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>1CA050D243B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E71E7CA-B577-47E8-A0EA-3B8050EE0037</gtr:id><gtr:title>A comparison of CT- and ultrasound-based imaging to localize the prostate for external beam radiotherapy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf5efc8b71f5001a4f8cc08071ef89d6"><gtr:id>bf5efc8b71f5001a4f8cc08071ef89d6</gtr:id><gtr:otherNames>McNair HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>32EB25DFB34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>130FC046-EBE3-40F2-91C5-4F1C0A7E2181</gtr:id><gtr:title>Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d97dd128860e0c1bd54c490b783283c"><gtr:id>8d97dd128860e0c1bd54c490b783283c</gtr:id><gtr:otherNames>Camp NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>C95512F71D6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>899D4396-3DB2-44BA-955B-57E6D8534B45</gtr:id><gtr:title>Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>99EBD449513</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BD020F4-AC8A-4DD8-A1ED-B0660E5D22D7</gtr:id><gtr:title>Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ae4b9f57e5711d5384674dd031f3c1e"><gtr:id>8ae4b9f57e5711d5384674dd031f3c1e</gtr:id><gtr:otherNames>Mangar SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>E6424EEDCB5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA2F5269-C8ED-4109-BB12-ED9B7FAAA2DA</gtr:id><gtr:title>Sox9 is required for prostate development.</gtr:title><gtr:parentPublicationTitle>Developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce350f910b3fbceb089e8788fa4f4651"><gtr:id>ce350f910b3fbceb089e8788fa4f4651</gtr:id><gtr:otherNames>Thomsen MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-1606</gtr:issn><gtr:outcomeId>C077F3399C7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81598A6E-780B-4B7A-B1C9-3500C03370B5</gtr:id><gtr:title>Urological referral of asymptomatic men in general practice in England.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/116576ae71b70349068564a6f9700df5"><gtr:id>116576ae71b70349068564a6f9700df5</gtr:id><gtr:otherNames>Melia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>C5BE273F27A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BE2D784-A35D-4F98-A918-E9E211A9A22B</gtr:id><gtr:title>Isolation of genes controlling apoptosis through their effects on cell survival.</gtr:title><gtr:parentPublicationTitle>Gene therapy &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1acf39a83094a65d3848318c2954b2ae"><gtr:id>1acf39a83094a65d3848318c2954b2ae</gtr:id><gtr:otherNames>Williams GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1529-9120</gtr:issn><gtr:outcomeId>0FF1187F564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84097500-42CE-4DD5-975E-F9F02F1BBC40</gtr:id><gtr:title>Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>1CF879EC7FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F729924-B038-442F-AEB5-AF68773CE62C</gtr:id><gtr:title>Additional treatment for pT3 prostate cancer: now, later or never.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8447810d2996b427fd4ebb6f4631191"><gtr:id>d8447810d2996b427fd4ebb6f4631191</gtr:id><gtr:otherNames>Dearnaley DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>007B779744B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CACDF723-7E66-48E8-8DE7-F5E89CADC0FB</gtr:id><gtr:title>Multiple loci on 8q24 associated with prostate cancer susceptibility.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7bcfe6bc5eafd47514c917314a7dc3fd"><gtr:id>7bcfe6bc5eafd47514c917314a7dc3fd</gtr:id><gtr:otherNames>Al Olama AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>D59123E7279</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7C5BD65-1073-4007-BE02-0E0CC291BB68</gtr:id><gtr:title>Active surveillance with selective radical treatment for localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Cancer journal (Sudbury, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58d5f9d487d1e3e8e1eddf3ebc47094b"><gtr:id>58d5f9d487d1e3e8e1eddf3ebc47094b</gtr:id><gtr:otherNames>van As NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1528-9117</gtr:issn><gtr:outcomeId>1EE15558D42</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D1FC463-213D-4615-B175-17299FBEA9F6</gtr:id><gtr:title>STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e8a186efc2c3999987d8d9c65f0361"><gtr:id>03e8a186efc2c3999987d8d9c65f0361</gtr:id><gtr:otherNames>James ND</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>9FEB502C9A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>605F453F-59F6-469B-9ADB-4D674E9D52AC</gtr:id><gtr:title>Radiosensitivity, radiogenomics and RAPPER.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d9390b0c0b53671de712307f15a06f1"><gtr:id>6d9390b0c0b53671de712307f15a06f1</gtr:id><gtr:otherNames>Burnet NG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>04630FE0B66</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>104BF295-53DB-4244-9A75-C269E68DA7AB</gtr:id><gtr:title>The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/116576ae71b70349068564a6f9700df5"><gtr:id>116576ae71b70349068564a6f9700df5</gtr:id><gtr:otherNames>Melia J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>88A18EFC58C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3304AB8-4C34-4724-B6CA-CA89A03E88B3</gtr:id><gtr:title>Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf1513b0c6d9acc01d11fa40a454fa02"><gtr:id>cf1513b0c6d9acc01d11fa40a454fa02</gtr:id><gtr:otherNames>Travis RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>E2FB4D09692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>382C2181-7310-49C7-9F1F-206589C4227F</gtr:id><gtr:title>Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>798D6EDBFAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56D31F1A-5E75-4D57-8BC3-DEF885698B21</gtr:id><gtr:title>Primary colorectal tumors fail to express the proapoptotic mediator PTAG and its reexpression augments drug-induced apoptosis.</gtr:title><gtr:parentPublicationTitle>Genes, chromosomes &amp; cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/def09a96734470903b8a39498d4bb4e6"><gtr:id>def09a96734470903b8a39498d4bb4e6</gtr:id><gtr:otherNames>Bahar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1045-2257</gtr:issn><gtr:outcomeId>A1D69F1AB75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46375631-A29F-4766-9EBF-2FCD5709F48B</gtr:id><gtr:title>Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16814043ec456bd5ba7f487db967d795"><gtr:id>16814043ec456bd5ba7f487db967d795</gtr:id><gtr:otherNames>Raynaud FI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>F0B20DEC9FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5A57165-5BDB-4367-8D3E-7E6259C394E8</gtr:id><gtr:title>ETS gene fusions in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88f14debdf5750d7f11749ac6e7af69b"><gtr:id>88f14debdf5750d7f11749ac6e7af69b</gtr:id><gtr:otherNames>Clark JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>BDA342B1C00</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6F7D7D7-169A-4141-840F-C9332049E422</gtr:id><gtr:title>Identification of a new prostate cancer susceptibility locus on chromosome 8q24.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eec527a042a7aa99b169841d30f68880"><gtr:id>eec527a042a7aa99b169841d30f68880</gtr:id><gtr:otherNames>Yeager M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>D3FA461EC9B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0B80ED3-E89B-441B-9581-C7A20BFEA5BE</gtr:id><gtr:title>Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1144a838a8adde77965408edee381478"><gtr:id>1144a838a8adde77965408edee381478</gtr:id><gtr:otherNames>Roemeling S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>E1773FFDF6C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>061FDA63-A22D-4286-A225-0D71C1FF8CA2</gtr:id><gtr:title>Citrate transport and metabolism in mammalian cells: prostate epithelial cells and prostate cancer.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab2e06488f928c16acba186c511dcd19"><gtr:id>ab2e06488f928c16acba186c511dcd19</gtr:id><gtr:otherNames>Mycielska ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn><gtr:outcomeId>D9EDA8F9E05</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EA37831-FE20-4C1A-B0CE-F9610E6F1C1E</gtr:id><gtr:title>Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>64FD202EB94</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BC2EC10-A2E1-4276-82D3-4795D57004EC</gtr:id><gtr:title>Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873).</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/89617b9d24b04255c06955063acd4a7c"><gtr:id>89617b9d24b04255c06955063acd4a7c</gtr:id><gtr:otherNames>Mason MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn><gtr:outcomeId>C9CA83C5BB0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F6670AB-B57B-4792-9330-32154F058124</gtr:id><gtr:title>Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36567bcc46fe396f47df964a7f62c1ad"><gtr:id>36567bcc46fe396f47df964a7f62c1ad</gtr:id><gtr:otherNames>Qiao J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>0B83B6EFA2C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>686B1371-14C3-43FF-800E-12084A2DE476</gtr:id><gtr:title>Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>The American journal of clinical nutrition</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a987d8fe811f020393f6d2a0d8ee023"><gtr:id>5a987d8fe811f020393f6d2a0d8ee023</gtr:id><gtr:otherNames>Crowe FL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0002-9165</gtr:issn><gtr:outcomeId>DDC0C01E0B1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC7E9DB4-CE53-4070-8485-FAA99EA1C6F5</gtr:id><gtr:title>Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f916785d45262e78b21f0f9e558423bf"><gtr:id>f916785d45262e78b21f0f9e558423bf</gtr:id><gtr:otherNames>Vergis R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>625687261B5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>906C14AD-F2E9-4E46-BADB-DDBA9E1FE30F</gtr:id><gtr:title>Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/781a52d1f6e701f1834be81201f4c8e7"><gtr:id>781a52d1f6e701f1834be81201f4c8e7</gtr:id><gtr:otherNames>Lloyd MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>B1045C0C508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C890D35B-4B41-4F41-BB30-C91E609BC373</gtr:id><gtr:title>Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d895db59e431e55ec84105d0da4fab0d"><gtr:id>d895db59e431e55ec84105d0da4fab0d</gtr:id><gtr:otherNames>Zhang Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>B6AEF683805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72EFC615-9978-4C2F-B9E0-A8D94C4982BE</gtr:id><gtr:title>A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69f22ed18ed78e178dcd5bd8d5c696e8"><gtr:id>69f22ed18ed78e178dcd5bd8d5c696e8</gtr:id><gtr:otherNames>Suzuki R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>9E504F17603</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>443FE0A0-6B67-4B23-A944-655B36725441</gtr:id><gtr:title>Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d9603b8918dceb92094532bf53a9826"><gtr:id>1d9603b8918dceb92094532bf53a9826</gtr:id><gtr:otherNames>Horwich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>B00198DEE97</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A042B1F2-2E63-46F1-A035-C40975759DB6</gtr:id><gtr:title>Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b4a7c1c5c1030a604bcaa7fb99606bc"><gtr:id>1b4a7c1c5c1030a604bcaa7fb99606bc</gtr:id><gtr:otherNames>Eastham JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>77B2C6B764B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0567AE76-DDD5-42D7-80D7-0577F61023CB</gtr:id><gtr:title>Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c2ec53951262fd33c9621bc7ce775f7"><gtr:id>8c2ec53951262fd33c9621bc7ce775f7</gtr:id><gtr:otherNames>Roobol MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>74D44367240</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EAB6FD3F-DA26-4EA5-A63A-CE60829BB240</gtr:id><gtr:title>Alcohol consumption and the risk for prostate cancer in the European Prospective Investigation into Cancer and Nutrition.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5600774a3c70bb82c6bbe1ef3ee1253e"><gtr:id>5600774a3c70bb82c6bbe1ef3ee1253e</gtr:id><gtr:otherNames>Rohrmann S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn><gtr:outcomeId>8F4331529C5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADE8F19D-4991-4C81-A969-3636C70B1355</gtr:id><gtr:title>A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c5ee83798ec61595b58e2bb52b33b97"><gtr:id>8c5ee83798ec61595b58e2bb52b33b97</gtr:id><gtr:otherNames>Attard G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>20E3BB0FD8E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>76103482-79DA-4E46-B047-4A169F0AF9FD</gtr:id><gtr:title>Candidate tumor suppressor LUCA-15/RBM5/H37 modulates expression of apoptosis and cell cycle genes.</gtr:title><gtr:parentPublicationTitle>Experimental cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c69e0118dcdf559e4f85b0f777ea6e3"><gtr:id>6c69e0118dcdf559e4f85b0f777ea6e3</gtr:id><gtr:otherNames>Mourtada-Maarabouni M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-4827</gtr:issn><gtr:outcomeId>E7E50440787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D1320C5-7B68-42B5-8EC4-7170972FDC6E</gtr:id><gtr:title>Quantification of phase I/II metabolizing enzyme gene expression and polycyclic aromatic hydrocarbon-DNA adduct levels in human prostate.</gtr:title><gtr:parentPublicationTitle>The Prostate</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/691c424fb9a21c045cbf1afbfceeefbf"><gtr:id>691c424fb9a21c045cbf1afbfceeefbf</gtr:id><gtr:otherNames>John K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-4137</gtr:issn><gtr:outcomeId>18A8859710A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9C3D5B-6A4F-4EA3-BA0A-B5F9FC599252</gtr:id><gtr:title>Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee7aef91053644ad2fbfd7c6c127b621"><gtr:id>ee7aef91053644ad2fbfd7c6c127b621</gtr:id><gtr:otherNames>Parker C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>7FD0A82F873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>214EEC5B-1939-4BC3-899B-4B44EE343721</gtr:id><gtr:title>Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66b43fb2d29e926172c8f9e8f4179f43"><gtr:id>66b43fb2d29e926172c8f9e8f4179f43</gtr:id><gtr:otherNames>Milosevic M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>42153F9B45A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB7F7279-0628-425D-A48E-B42DD6277693</gtr:id><gtr:title>Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics.</gtr:title><gtr:parentPublicationTitle>Human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/654229500b0d265ff9ed8d1b79c3f513"><gtr:id>654229500b0d265ff9ed8d1b79c3f513</gtr:id><gtr:otherNames>Schaid DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0340-6717</gtr:issn><gtr:outcomeId>1530BA3B9BD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16B2C993-C189-487A-B150-CFA682974447</gtr:id><gtr:title>Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular cancer therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f52fdf7de8e242ea40fb6b766cf424b4"><gtr:id>f52fdf7de8e242ea40fb6b766cf424b4</gtr:id><gtr:otherNames>Beloueche-Babari M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-7163</gtr:issn><gtr:outcomeId>AF639A399DA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B132D247-02B1-4C4D-A1DF-94CD18E572A7</gtr:id><gtr:title>Does active surveillance for men with localized prostate cancer carry psychological morbidity?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/602e19ddbc41c3f26dfe5c89e60a0468"><gtr:id>602e19ddbc41c3f26dfe5c89e60a0468</gtr:id><gtr:otherNames>Burnet KL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>252B53A9504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDA67F5B-416E-4673-BA74-4DD13735436B</gtr:id><gtr:title>Nerve growth factor enhances voltage-gated Na+ channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491a4a051028639fe5a363c4f1372e9a"><gtr:id>491a4a051028639fe5a363c4f1372e9a</gtr:id><gtr:otherNames>Brackenbury WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>C3E797F2EF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01FBB39D-3A1D-452D-8F19-489D6F068612</gtr:id><gtr:title>Increased Id-1 expression is significantly associated with poor survival of patients with prostate cancer.</gtr:title><gtr:parentPublicationTitle>Human pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc2d8d91bf879d884ccff7f7d338a070"><gtr:id>dc2d8d91bf879d884ccff7f7d338a070</gtr:id><gtr:otherNames>Forootan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0046-8177</gtr:issn><gtr:outcomeId>D295530B5FA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE935A28-FD1E-47F2-A7CE-FD8CE1BF5C42</gtr:id><gtr:title>Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.</gtr:title><gtr:parentPublicationTitle>Annals of oncology : official journal of the European Society for Medical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba174fa18168bab0b7fd8a0f1bfa13c"><gtr:id>fba174fa18168bab0b7fd8a0f1bfa13c</gtr:id><gtr:otherNames>ESMO Guidelines Working Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0923-7534</gtr:issn><gtr:outcomeId>67A8C39057C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C652231-A05C-4661-9A1E-D8E77E78F0E2</gtr:id><gtr:title>The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e023955a5f4663f8ce1f592b9242603e"><gtr:id>e023955a5f4663f8ce1f592b9242603e</gtr:id><gtr:otherNames>Whittaker SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>E7FF117CCC1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFCCAB60-EDC5-43D6-ABB0-DE268DB72376</gtr:id><gtr:title>Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e46ef7cf2b1a9aa57b3d01ad597fc6f"><gtr:id>8e46ef7cf2b1a9aa57b3d01ad597fc6f</gtr:id><gtr:otherNames>Jhavar S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>D4FE4998309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DB8550D-AC95-4015-8B6E-7D5F49112918</gtr:id><gtr:title>Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.</gtr:title><gtr:parentPublicationTitle>Annals of internal medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/93ba6cad88ac200722f89e1a5844f7bb"><gtr:id>93ba6cad88ac200722f89e1a5844f7bb</gtr:id><gtr:otherNames>Roddam AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-4819</gtr:issn><gtr:outcomeId>AF45D6B42A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBAF5C96-9A27-42C2-8CF0-71D8CBFB2D8C</gtr:id><gtr:title>Hypofractionation in clinical trials for prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/282b6a9992778afd7aafc983d69695da"><gtr:id>282b6a9992778afd7aafc983d69695da</gtr:id><gtr:otherNames>Hoskin PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>8F6A403329E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47548364-D5D2-42AD-8B43-F78BDAC76911</gtr:id><gtr:title>The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/491a4a051028639fe5a363c4f1372e9a"><gtr:id>491a4a051028639fe5a363c4f1372e9a</gtr:id><gtr:otherNames>Brackenbury WJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>pm_540e145e145671b51</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FD79941-DDBB-48E6-B2C1-80D88F6869D3</gtr:id><gtr:title>Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Clinical radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/400e14fcc663e3a6814fb1d70dce02bf"><gtr:id>400e14fcc663e3a6814fb1d70dce02bf</gtr:id><gtr:otherNames>deSouza NM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0009-9260</gtr:issn><gtr:outcomeId>06F8720EBBA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0940C927-CE49-477B-88BC-44FE13D045CD</gtr:id><gtr:title>A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/08733fc2dc3be9852e7feefcb458c91b"><gtr:id>08733fc2dc3be9852e7feefcb458c91b</gtr:id><gtr:otherNames>Lee CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>E7C50F7EEE1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93534225-8E8C-411C-AC4A-052C9989EC6D</gtr:id><gtr:title>AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell lines.</gtr:title><gtr:parentPublicationTitle>Chemical research in toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e8b40616353da08626057f148532391"><gtr:id>5e8b40616353da08626057f148532391</gtr:id><gtr:otherNames>Hockley SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0893-228X</gtr:issn><gtr:outcomeId>E9C286E94B2</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501019</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>